Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087958
Status:
COMPLETED
Last Update Posted:
2009-05-01
First Post:
2004-07-16
Brief Title:
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline Taxane and Capecitabine Treatment
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Phase II Multi-Center Open-Label Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines Taxanes and Capecitabine
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to determine if the investigational drug is able to reduceshrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines taxanes and capecitabine
Detailed Description:
All patients in this trial will receive the investigational chemotherapy drug at an optimal dose as determined by previous clinical trials The investigational drug is given through a vein once every three weeks This drug prevents tumor cells from dividing so they may stop growing or die
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2004-000572-14 | None | None | None |
| XRP9881B2001 | None | None | None |